P73 protein in carcinogenesis and response to anti-tumor therapy

Волницкий А.В., Виноградская Г.Р., Филатов М.В. Экспрессия гена р73 в глиомах // Вопр. онкол. - 2012. -Т. 58 (4). - С. 545-549.

Agami R., Blandino G., Oren M., Shaul Y. Interaction of c-Abl and p73alpha and their collaboration to induce apoptosis // Nature. - 1999. - Vol. 399. - P. 809-813.

Agostino S.Di., Cortese G., Monti O. et al. The disruption of the protein complex mutantp53/p73 increases selectivity the response of tumor cells to anticancer drugs // Cell Cycle. - 2008. - Vol. 7. - P. 3440-3447.

Basu S., Totty N.F., Irwin M.S. et al. Akt phosphorylates the Yes-associated protein, YAP, to induce interaction with 14-3-3 and attenuation of p73-mediated apoptosis // Mol. Cell. - 2003. - Vol. 11. - P. 11-23.

Beitzinger M., Hofmann L., Oswald C. et al. P73 poses a barrier to malignant transformation by limiting anchorage-independent growth // EMBO J. - 2008. -Vol. 27. - P. 792-803.

Bell H.S., Dufes Ch., O’Prey J. et al. A p53-derived apoptotic peptide derepresses p73 to cause tumor regression in vivo // J. Clin. Invest. - 2007. - Vol. 117. - P. 1008-1018.

Buhlmann S., Putzer B.M. DNp73 a matter of cancer: mechanisms and clinical implication // Biochim. Biophys. Acta. - 2 008. - Vol. 1785. - P. 207-216.

Castellino R.C., de Bortoli M., Lin L.L. et al. Overexpressed TP73 induces apoptosis in medulloblastoma // BMC Cancer. - 2007. - Vol. 7. - P. 127-142.

Castillo J., Goni S., Latasa M.U. et al. Amphiregulin induces the alternative splicing of p73 into its oncogenic isoform AEx2p73 in human hepatocellular tumors // Gas troenterology. - 2009. - Vol. 137. - P. 1805-1815.

Chan W.M., Siu W.Y., Lau A., Poon R.Y. How many mutant p53 molecules are needed to inactivate a tetramer? // Mol. Cell Biol. - 2004. - Vol. 24. - P. 3536-3551.

Concin N., Becker K., Slade N. et al. Transdominant ATAp73 isoforms are frequently up-regulated in ovarian cancer: Evidence for their role as epigenetic p53 inhibitors in vivo // Cancer Res. — 2004. - Vol. 64. — P. 2449-2460.

Costanzo A., Merlo P., Pediconi N. et al. DNA damage-dependent acetylation of p73 dictates the selective activation of apoptotic target genes // Mol. Cell. — 2002. — Vol. 9. — P. 175-186.

Dar A.A., Belkhiri A., Ecsedy J. et al. Aurora kinase A inhibition leads to p73-dependent apoptosis in p53-deficient cancer cells // Cancer Res. — 2008. — Vol. 68. — P. 8998-9004.

Dong S., Pang J.C., Hu J. et al. Transcriptional inactivation of TP73 expression in oligodendroglial tumors // Int. J. Cancer. — 2002. — Vol. 98. — P. 370-375.

Emmrich S., Wang W., John K. et al. Antisense gapmers selectively suppress individual oncogenic p73 splice isoforms and inhibit tumor growth in vivo // Mol. Cancer. — 2009. — Vol. 8. - P. 61-73.

Faredoni-Laurens L., Tourpin S., Alsafadi S. et al. Involvement of N-terminally truncated variants of p73, ATAp73, in head and neck squamous cell cancer // Cell Cycle. — 2008. — Vol. 7. — P. 1587-1596.

Ichimura K., Vogazianou A.P., Liu L. et al. P36 is preferential target of chromosome 1 deletions in astrocytic tumours and homozygously deleted in a subset of glioblastomas // Oncogene. — 2008. — Vol. 27. — P. 97-108.

Irwin M.S., Kondo K., Marin M.C. et al. Chemosensitivity linked to p73 function // Cancer Cell. - 2003. — Vol. 3. — P. 403-410.

Johnson J., Lagowski J., Sundberg A. et al. P73 loss triggers conversion to squamous cell carcinoma reversible upon reconstitution with TAp73a // Cancer Res. — 2007. — Vol. 67. — P. 7723-7730.

Kaghad M., Bonnet H., Yang A. et al. Monoallelically expressed gene related to p53 at 1p36, a region frequently deleted in neuroblastoma and other human cancers // Cell. — 1997. — Vol. 90. — P. 809-819.

Kravchenko J.E., Ilyinskaya G.V., Komarov PG. et al. Small-molecule RETRA suppresses mutant p53-bearing cancer cells through a p73-dependent salvage pathway // PNAS USA / —2008. — Vol. 105. — P. 6302-6307.

Lane D.P., Crawford L.V. T antigen is bound to a host protein in SV40-transformed cells // Nature. - 1978. — Vol. 278. — P. 261-263.

Lane D.P. Cancer. p53, guardian of the genome // Nature. — 1992. — Vol. 358. — P. 15-16.

Lau L.M.S., Wolter J.K., Lau J.T.M.L. et al. Cyclooxygenase inhibitors differentially modulate p73 isoforms in neuroblastoma // Oncogene. — 2009. — Vol. 28. — P. 2024-2033.

Leong C.O., Vidnovic N., deYoung M.P. et al. The p63/p73 network mediates chemosensitivity to cisplatin in a biologically defined subset of primary breast cancer // J. Clin. Invest. — 2007. — Vol. 117. — P. 1370-1380.

Levy D., Adamovich Y., Reuven N., Shaul Y.The Yes-associated protein 1 stabilizes p73 by preventing Itch-mediated ubiquitination of p73 // Cell. Death Differ. - 2007. — Vol. 14. — P. 743-751.

Levy D., Adamovich Y., Reuven N., Shaul Y. Yap 1 phosphorylation by c-Abl is a critical step in selective activation of proapoptotic genes in response to DNA damage // Mol. Cell. — 2008. — Vol. 29. — P. 350 -361.

Lunghi P., Costanzo A., Mazzera L. et al. The p53 family protein p73 provides new insights into cancer chemosensitivity and targeting // Clin. Cancer Res. — 2009. — Vol. 15. — P. 6495-6502.

Maisse C., Munarriz E., Barcaroli D. et al. DNA damage induces the rapid and selective degradation of the ANp73 isoform, allowing apoptosis to occur // Cell Death Differ. — 2004. — Vol. 11. — P. 685-687.

Mantovani F., Piazza S., Gostissa M. et al. Pin1 links the activities of c-Abl and p300 in regulating p73 function // Mol. Cell. — 2004. — Vol. 14. — P. 625-636.

Marabese M., Vikhanskaya F., Broggini M. P73: A chiaroscuro gene in cancer // Eur. J. Cancer. -2007 — Vol. 43. — P. 1361-1372.

Meier M., den Boer M.L., Meijerink J.P.P. et al. Differential expression of p73 isoforms in relation to drug resistance in childhood T-lineage acute lymphoblastic leukaemia // Leukemia. — 2006. — Vol. 20. — P. 1377-1384.

Muller M., Schleithoff E.S., Stremmel W. et al. One, two, three — p53, p63, p73 and chemosensitivity // Drug Resist. Updat. - 2006. — Vol. 9. — P. 288-306.

Murray-Zmijewski F., Lane D.P., Bourdon J. - C. p53/p63/p73 isoforms: an orchestra of isoforms to harmonise cell differentiation and response to stress // Cell Death Dif. — 2006. — Vol. 13. — P. 962-972.

Niikura Y., Dixit A., Scott R. et al. BUB1 mediation of caspase-independent mitotic death determines cell fate // J. Cell Biol. — 2007. — Vol. 178. — P. 283-296.

Ory B., Ellisen L.W. A microRNA-dependent circuit controlling p63/p73 homeostasis: p53 family cross-talk meets therapeutic opportunity // Oncotarget. — 2011. — Vol. 2. — P. 259-264.

Ory B., Ramsey M.R., Wilson C. et al. A microRNA-dependent program controls p53-independent survival and chemosensitivity in human and murine squamous cell carcinoma // J. Clin. Invest. - 2011. - Vol. 121. — P. 809-820.

Oswald C., Stiewe Th. In good time and bad // Cell Cycle. — 2008. — Vol. 7. — P. 1726-1731.

Pietsch E.Ch., Sykes S.M., MaMahon S.B., Murphy M.E. The p53 family and programmed cell death // Oncogene. — 2008. — Vol. 27. — P. 6507-6521.

Pinon J.D., Labi V., Egle A., Villunger A. Bim and Bmf in tissue homeostasis and malignant disease // Oncogene. — 2008. — Vol. 27 (Suppl 1). - S. 41-52.

Sampath D., Calin G.A., Puduvalli V.K. et al. Specific activation of microRNA106b enables the p73 apoptotic response in chronic lymphocytic leukemia by targeting the ubiquitin ligase Itch for degradation // Blood. — 2009. — Vol. 113. — P. 3744-3753.

Sanchez- Prieto R., Sanchez-Arevalo V.J., Servitja J.M., Gutkind J.S. Regulation of p73 by c-Abl through the p38 MAP kinase pathway // Oncogene. — 2002. — Vol. 21. — P. 974-979.

Seelan R.S., Irwin M., van der Qian C. S.P. et al. The human p73 promoter: characterization and identification of functional E2F binding sites // Neoplasia. — 2002. — Vol. 4. — P. 195-203.

Toh W.H., Nam S.Y., Sabapathy K. An essential role for p73 in regulating mitotic cell death // Cell Death Differ. — 2010. — Vol. 17. — P. 787-800.

Tomasini R., Tsuchihara K., Tsuda C. et al. TAp73 regulates the spindle assembly checkpoint by modulating BubR1 activity // PNAS USA. — 2009. — Vol. 106. — P. 797-802.

Vernole P., Neale M.H., Barcaroli D. et al. TAp73alpha binds the kinetochore proteins Bub1 and Bub3 resulting in polyploidy // Cell Cycle. — 2009. — Vol. 8. — P. 421-429.

M. Wager, J. Guilhot, J. - L. Blanc et al. (2006). Prognostic value of increase in transcript levels of Tp73AEx2-3 isoforms in low-grade glioma patients. Br. J. Cancer 95: 1062-1069.

Yang A., Kaghad M., Wang Y. et al. p63, a p53 homolog at 3q27-29, encodes multiple products with transactivating, death-inducing, and dominant-negative activities // Mol. Cell. — 1998. — Vol. 2. — P. 305-316.

Zaika A., Slade N., Erster S.H. et al. ANp73, a dominant negative inhibitor of wild type p53 and TAp73 isoforms, is upregulated in human tumors // J. Exp. Med. — 2002. — Vol. 196. — P. 765-780.